Hologic (HOLX) Stock Forecast, Price Target & Predictions
HOLX Stock Forecast
Hologic stock forecast is as follows: an average price target of $78.92 (represents a -3.25% downside from HOLX’s last price of $81.57) and a rating consensus of 'Buy', based on 15 wall street analysts offering a 1-year stock forecast.
HOLX Price Target
The average price target for Hologic (HOLX) is $78.92 based on 1-year price targets from 15 Wall Street analysts in the past 3 months, with a price target range of $95.00 to $33.00. This represents a potential -3.25% downside from HOLX's last price of $81.57.
HOLX Analyst Ratings
According to 15 Wall Street analysts, Hologic's rating consensus is 'Buy'. The analyst rating breakdown for HOLX stock is 0 'Strong Buy' (0.00%), 11 'Buy' (73.33%), 4 'Hold' (26.67%), 0 'Sell' (0.00%), and 0 'Strong Sell' (0.00%).
Hologic Price Target by Analyst
| Date | Analyst | Company | Price Target | Price when Published | Price Target/Price when Published | Price Target/Last Closing Price |
|---|---|---|---|---|---|---|
| Jul 30, 2024 | Mike Matson | Needham | $90.00 | $80.84 | 11.33% | 10.33% |
| Jul 02, 2024 | Vijay Kumar | Evercore ISI | $76.00 | $74.10 | 2.56% | -6.83% |
| Jun 27, 2024 | Ian Zaffino | Oppenheimer | $33.00 | $73.06 | -54.83% | -59.54% |
| May 09, 2024 | David Toung | Argus Research | $95.00 | $75.86 | 25.23% | 16.46% |
| Feb 02, 2023 | - | Cowen & Co. | $95.00 | $83.77 | 13.41% | 16.46% |
| Jan 10, 2023 | - | Wells Fargo | $80.00 | $81.07 | -1.32% | -1.92% |
| Dec 07, 2022 | - | RBC Capital | $75.00 | $74.22 | 1.05% | -8.05% |
| Jul 28, 2022 | - | Morgan Stanley | $70.00 | $70.86 | -1.21% | -14.18% |
| Jul 28, 2022 | - | Raymond James | $80.00 | $71.31 | 12.19% | -1.92% |
| May 17, 2022 | - | Leerink Partners | $85.00 | $77.22 | 10.08% | 4.20% |
The latest Hologic stock forecast, released on Jul 30, 2024 by Mike Matson from Needham, set a price target of $90.00, which represents a 11.33% increase from the stock price at the time of the forecast ($80.84), and a 10.33% increase from HOLX last price ($81.57).
Hologic Price Target by Period
| 1M | 3M | 12M | |
|---|---|---|---|
| # Anlaysts | - | 3 | 4 |
| Avg Price Target | - | $66.33 | $73.50 |
| Last Closing Price | $81.57 | $81.57 | $81.57 |
| Upside/Downside | -100.00% | -18.68% | -9.89% |
In the current month, the average price target of Hologic stock is -, according to 0 Wall Street analyst offering twelve months forecast. The average price target represents a -100.00% decrease as opposed to Hologic's last price of $81.57. This month's average price target is down -100.00% compared to last quarter, and down -100.00% compared to last year.
Analyst Ratings Upgrades/Downgrades
| Date | Company | Previous Rating | New Rating | Rating Change |
|---|---|---|---|---|
| Jul 30, 2024 | Barclays | Equal-Weight | Equal-Weight | Hold |
| Jul 30, 2024 | Benchmark | Buy | Buy | Hold |
| Jul 30, 2024 | Susquehanna | Positive | Positive | Hold |
| Jul 30, 2024 | Needham | Buy | Buy | Hold |
| Jul 30, 2024 | Keefe, Bruyette & Woods | Overweight | Overweight | Hold |
| Jul 30, 2024 | RBC Capital | Buy | Buy | Hold |
| Jul 30, 2024 | Wells Fargo | Overweight | Overweight | Hold |
| Jul 30, 2024 | Stephens | Sector Perform | Sector Perform | Hold |
| Jul 30, 2024 | BTIG | Neutral | Neutral | Hold |
| Jul 30, 2024 | RBC Capital | Sector Perform | Sector Perform | Hold |
Hologic's last stock rating was published by Barclays on Jul 30, 2024. The company gave HOLX a "Equal-Weight" rating, the same as its previous rate.
Hologic Financial Forecast
Hologic Revenue Forecast
| Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | Jun 19 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | - | - | - | $277.90M | $945.30M | $984.40M | $1.03B | $1.07B | $953.30M | $1.00B | $1.44B | $1.47B | $1.32B | $1.17B | $1.54B | $1.61B | $1.35B | $822.90M | $756.10M | $850.50M | $865.80M | $852.40M |
| Avg Forecast | $1.11B | $1.14B | $1.13B | $1.13B | $1.05B | $1.07B | $1.06B | $1.06B | $979.15M | $1.00B | $1.00B | $989.32M | $940.00M | $960.25M | $956.44M | $1.00B | $862.09M | $903.31M | $1.29B | $1.19B | $1.04B | $1.04B | $1.54B | $1.40B | $1.12B | $616.70M | $745.85M | $845.09M | $846.02M | $835.02M |
| High Forecast | $1.11B | $1.14B | $1.13B | $1.13B | $1.05B | $1.08B | $1.06B | $1.06B | $1.01B | $1.00B | $1.00B | $1.02B | $951.96M | $962.48M | $958.66M | $1.01B | $864.09M | $916.43M | $1.31B | $1.21B | $1.06B | $1.05B | $1.56B | $1.42B | $1.14B | $625.66M | $756.69M | $857.37M | $858.31M | $847.15M |
| Low Forecast | $1.10B | $1.13B | $1.12B | $1.12B | $1.05B | $1.07B | $1.06B | $1.05B | $972.10M | $997.95M | $997.89M | $976.49M | $927.37M | $956.56M | $952.77M | $1.00B | $858.78M | $898.23M | $1.28B | $1.19B | $1.04B | $1.03B | $1.53B | $1.39B | $1.11B | $613.23M | $741.66M | $840.34M | $841.26M | $830.32M |
| # Analysts | 8 | 8 | 8 | 7 | 7 | 7 | 7 | 8 | 10 | 8 | 3 | 6 | 14 | 12 | 7 | 6 | 6 | 7 | 6 | 7 | 10 | 7 | 12 | 12 | 8 | 8 | 8 | 5 | 5 | 5 |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | 0.28% | 1.01% | 1.03% | 1.07% | 1.07% | 1.11% | 1.11% | 1.11% | 1.23% | 1.26% | 1.13% | 1.00% | 1.15% | 1.20% | 1.33% | 1.01% | 1.01% | 1.02% | 1.02% |
Hologic's average Quarter revenue forecast for Mar 24 based on 3 analysts is $1.00B, with a low forecast of $997.89M, and a high forecast of $1.00B. HOLX's average Quarter revenue forecast represents a 260.47% increase compared to the company's last Quarter revenue of $277.90M (Dec 23).
Hologic EBITDA Forecast
| Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | Jun 19 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 8 | 8 | 8 | 7 | 7 | 7 | 7 | 8 | 10 | 8 | 3 | 6 | 14 | 12 | 7 | 6 | 6 | 7 | 6 | 7 | 10 | 7 | 12 | 12 | 8 | 8 | 8 | 5 | 5 | 5 |
| EBITDA | - | - | - | - | - | - | - | - | - | - | - | $198.20M | $305.50M | $1.40M | $376.70M | $354.20M | $208.70M | $345.90M | $702.90M | $752.40M | $450.90M | $463.80M | $883.90M | $984.60M | $662.80M | $290.40M | $246.80M | $229.90M | $99.30M | $265.40M |
| Avg Forecast | $402.82M | $413.90M | $410.62M | $410.43M | $382.57M | $391.16M | $386.90M | $385.14M | $356.85M | $365.10M | $600.84M | $360.55M | $342.58M | $349.96M | $546.22M | $366.18M | $526.61M | $329.21M | $496.56M | $434.78M | $380.11M | $378.44M | $907.78M | $511.15M | $408.02M | $224.75M | $245.40M | $307.99M | $308.33M | $304.32M |
| High Forecast | $403.76M | $414.86M | $411.58M | $411.38M | $383.46M | $392.07M | $387.79M | $386.04M | $366.43M | $365.94M | $721.01M | $370.36M | $346.94M | $350.77M | $655.46M | $367.03M | $631.93M | $333.99M | $595.88M | $441.10M | $385.63M | $383.94M | $1.09B | $518.58M | $413.95M | $228.02M | $294.48M | $312.46M | $312.81M | $308.74M |
| Low Forecast | $401.28M | $412.32M | $409.05M | $408.86M | $381.10M | $389.66M | $385.41M | $383.66M | $354.28M | $363.70M | $480.67M | $355.87M | $337.97M | $348.61M | $436.98M | $364.77M | $421.29M | $327.35M | $397.25M | $432.34M | $377.97M | $376.31M | $726.22M | $508.28M | $405.73M | $223.49M | $196.32M | $306.25M | $306.59M | $302.61M |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | 0.55% | 0.89% | 0.00% | 0.69% | 0.97% | 0.40% | 1.05% | 1.42% | 1.73% | 1.19% | 1.23% | 0.97% | 1.93% | 1.62% | 1.29% | 1.01% | 0.75% | 0.32% | 0.87% |
3 analysts predict HOLX's average Quarter EBITDA for Mar 24 to be $600.84M, with a high of $721.01M and a low of $480.67M. This is 203.15% upper than Hologic's previous annual EBITDA (Dec 23) of $198.20M.
Hologic Net Income Forecast
| Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | Jun 19 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 8 | 8 | 8 | 7 | 7 | 7 | 7 | 8 | 10 | 8 | 3 | 6 | 14 | 12 | 7 | 6 | 6 | 7 | 6 | 7 | 10 | 7 | 12 | 12 | 8 | 8 | 8 | 5 | 5 | 5 |
| Net Income | - | - | - | - | - | - | - | - | - | - | - | $246.50M | $90.60M | $-40.50M | $218.50M | $187.40M | $118.70M | $228.40M | $455.70M | $499.20M | $328.80M | $268.40M | $619.90M | $654.40M | $495.00M | $137.90M | $96.30M | $386.10M | $39.90M | $93.90M |
| Avg Forecast | $290.56M | $291.26M | $286.84M | $278.81M | $269.52M | $269.33M | $262.73M | $251.58M | $239.47M | $240.57M | $389.42M | $224.62M | $198.68M | $210.28M | $354.02M | $215.56M | $314.19M | $168.01M | $321.84M | $313.08M | $237.34M | $264.70M | $627.00M | $512.54M | $290.72M | $91.25M | $96.30M | $143.75M | $153.51M | $144.73M |
| High Forecast | $291.43M | $292.13M | $287.71M | $279.66M | $270.34M | $270.14M | $263.52M | $252.34M | $241.82M | $241.30M | $467.31M | $231.72M | $208.14M | $210.91M | $424.83M | $216.21M | $377.02M | $171.18M | $386.21M | $319.00M | $241.82M | $269.70M | $752.40M | $522.22M | $296.21M | $92.98M | $115.56M | $146.46M | $156.41M | $147.47M |
| Low Forecast | $289.11M | $289.80M | $285.41M | $277.42M | $268.18M | $267.98M | $261.42M | $250.33M | $238.28M | $239.37M | $311.54M | $219.89M | $189.22M | $209.23M | $283.22M | $214.48M | $251.35M | $166.78M | $257.47M | $310.79M | $235.61M | $262.77M | $501.60M | $508.79M | $288.60M | $90.59M | $77.04M | $142.70M | $152.39M | $143.68M |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | 1.10% | 0.46% | -0.19% | 0.62% | 0.87% | 0.38% | 1.36% | 1.42% | 1.59% | 1.39% | 1.01% | 0.99% | 1.28% | 1.70% | 1.51% | 1.00% | 2.69% | 0.26% | 0.65% |
Hologic's average Quarter net income forecast for Mar 24 is $389.42M, with a range of $311.54M to $467.31M. HOLX's average Quarter net income forecast represents a 57.98% increase compared to the company's last Quarter net income of $246.50M (Dec 23).
Hologic SG&A Forecast
| Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | Jun 19 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 8 | 8 | 8 | 7 | 7 | 7 | 7 | 8 | 10 | 8 | 3 | 6 | 14 | 12 | 7 | 6 | 6 | 7 | 6 | 7 | 10 | 7 | 12 | 12 | 8 | 8 | 8 | 5 | 5 | 5 |
| SG&A | - | - | - | - | - | - | - | - | - | - | - | $260.70M | $232.40M | $240.00M | $243.20M | $272.00M | $256.50M | $244.20M | $271.90M | $265.30M | $294.50M | $260.00M | $220.40M | $219.50M | $221.30M | $208.80M | $177.10M | $233.40M | $225.50M | $223.50M |
| Avg Forecast | $248.49M | $255.33M | $253.31M | $253.18M | $236.00M | $241.30M | $238.67M | $237.59M | $220.13M | $225.22M | $232.36M | $222.42M | $211.33M | $215.88M | $211.23M | $225.89M | $281.41M | $203.08M | $192.03M | $268.21M | $234.48M | $233.45M | $222.92M | $315.32M | $251.70M | $138.64M | $177.10M | $189.99M | $190.20M | $187.73M |
| High Forecast | $249.07M | $255.92M | $253.89M | $253.77M | $236.55M | $241.86M | $239.22M | $238.14M | $226.05M | $225.74M | $278.83M | $228.47M | $214.02M | $216.38M | $253.48M | $226.41M | $337.69M | $206.03M | $230.44M | $272.10M | $237.89M | $236.84M | $267.51M | $319.90M | $255.36M | $140.66M | $212.52M | $192.75M | $192.96M | $190.45M |
| Low Forecast | $247.54M | $254.35M | $252.33M | $252.21M | $235.09M | $240.37M | $237.75M | $236.67M | $218.55M | $224.36M | $185.88M | $219.53M | $208.49M | $215.05M | $168.99M | $225.02M | $225.13M | $201.94M | $153.62M | $266.70M | $233.16M | $232.14M | $178.34M | $313.55M | $250.29M | $137.86M | $141.68M | $188.92M | $189.13M | $186.67M |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | 1.17% | 1.10% | 1.11% | 1.15% | 1.20% | 0.91% | 1.20% | 1.42% | 0.99% | 1.26% | 1.11% | 0.99% | 0.70% | 0.88% | 1.51% | 1.00% | 1.23% | 1.19% | 1.19% |
Hologic's average Quarter SG&A projection for Mar 24 is $232.36M, based on 3 Wall Street analysts, with a range of $185.88M to $278.83M. The forecast indicates a -10.87% fall compared to HOLX last annual SG&A of $260.70M (Dec 23).
Hologic EPS Forecast
| Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | Jun 19 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 8 | 8 | 8 | 7 | 7 | 7 | 7 | 8 | 10 | 8 | 3 | 6 | 14 | 12 | 7 | 6 | 6 | 7 | 6 | 7 | 10 | 7 | 12 | 12 | 8 | 8 | 8 | 5 | 5 | 5 |
| EPS | - | - | - | - | - | - | - | - | - | - | - | - | $0.37 | $-0.16 | $0.88 | $0.76 | $0.47 | $0.91 | $1.81 | $1.97 | $1.29 | $1.05 | $2.40 | $2.53 | $1.90 | $0.53 | $0.37 | $1.44 | $0.15 | $0.35 |
| Avg Forecast | $1.23 | $1.23 | $1.21 | $1.18 | $1.14 | $1.14 | $1.11 | $1.06 | $1.01 | $1.02 | $0.98 | $0.95 | $0.84 | $0.89 | $0.88 | $0.91 | $0.62 | $0.71 | $1.60 | $1.32 | $1.00 | $1.12 | $2.62 | $2.17 | $1.23 | $0.39 | $0.57 | $0.61 | $0.65 | $0.61 |
| High Forecast | $1.23 | $1.24 | $1.22 | $1.18 | $1.14 | $1.14 | $1.11 | $1.07 | $1.02 | $1.02 | $0.98 | $0.98 | $0.88 | $0.89 | $0.88 | $0.91 | $0.63 | $0.72 | $1.63 | $1.35 | $1.02 | $1.14 | $2.67 | $2.21 | $1.25 | $0.39 | $0.58 | $0.62 | $0.66 | $0.62 |
| Low Forecast | $1.22 | $1.23 | $1.21 | $1.17 | $1.13 | $1.13 | $1.11 | $1.06 | $1.01 | $1.01 | $0.97 | $0.93 | $0.80 | $0.88 | $0.87 | $0.91 | $0.62 | $0.71 | $1.59 | $1.31 | $1.00 | $1.11 | $2.60 | $2.15 | $1.22 | $0.38 | $0.57 | $0.60 | $0.64 | $0.61 |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | 0.00% | 0.44% | -0.18% | 1.00% | 0.83% | 0.75% | 1.28% | 1.13% | 1.49% | 1.29% | 0.94% | 0.92% | 1.17% | 1.55% | 1.37% | 0.65% | 2.37% | 0.23% | 0.57% |
According to 3 Wall Street analysts, Hologic's projected average Quarter EPS for Mar 24 is $0.98, with a low estimate of $0.97 and a high estimate of $0.98. This represents a 97680.00% increase compared to HOLX previous annual EPS of - (Dec 23).
Hologic Peer Comparison by Price Target
| Ticker | Company | Last Closing Price | Avg Price Target | Upside/Downside | Avg Rating |
|---|---|---|---|---|---|
| COO | Cooper Companies | $106.59 | $298.00 | 179.58% | Buy |
| ANGO | AngioDynamics | $7.17 | $17.00 | 137.10% | Buy |
| HAE | Haemonetics | $73.24 | $112.00 | 52.92% | Buy |
| NVST | Envista | $17.44 | $23.83 | 36.64% | Hold |
| TFX | Teleflex | $244.53 | $304.09 | 24.36% | Buy |
| BDX | Becton, Dickinson and Company | $232.67 | $280.55 | 20.58% | Buy |
| WST | West Pharmaceutical Services | $297.24 | $345.33 | 16.18% | Buy |
| ALC | Alcon | $94.66 | $93.34 | -1.39% | Buy |
| HOLX | Hologic | $81.57 | $78.92 | -3.25% | Buy |
| MMSI | Merit Medical Systems | $96.58 | $92.13 | -4.61% | Buy |
| RMD | ResMed | $244.87 | $209.33 | -14.51% | Hold |
| ICUI | ICU Medical | $162.32 | $135.00 | -16.83% | Buy |
| ATR | AptarGroup | $152.38 | $100.00 | -34.37% | Buy |
HOLX Forecast FAQ
Is Hologic a good buy?
Yes, according to 15 Wall Street analysts, Hologic (HOLX) is considered a 'Buy'. The rating consensus is based on 0 'Strong Buy' and 11 'Buy' recommendations, accounting for 73.33% of HOLX's total ratings.
What is HOLX's price target?
Hologic (HOLX) average price target is $78.92 with a range of $33 to $95, implying a -3.25% from its last price of $81.57. The data is based on 15 Wall Street analysts who provided a twelve-month price target estimate in the last three months.
Will Hologic stock go up soon?
According to Wall Street analysts' prediction for HOLX stock, the company can go down by -3.25% (from the last price of $81.57 to the average price target of $78.92), up by 16.46% based on the highest stock price target, and down by -59.54% based on the lowest stock price target.
Can Hologic stock reach $120?
HOLX's average twelve months analyst stock price target of $78.92 does not support the claim that Hologic can reach $120 in the near future.
What are Hologic's analysts' financial forecasts?
Hologic's analysts financial forecasts for the fiscal year (Sep 2025) are as follows: average revenue is $4.24B (high $4.25B, low $4.23B), average EBITDA is $1.55B (high $1.55B, low $1.54B), average net income is $1.05B (high $1.06B, low $1.05B), average SG&A $953.55M (high $955.76M, low $949.89M), and average EPS is $4.45 (high $4.47, low $4.43). HOLX's analysts financial forecasts for the fiscal year (Sep 2026) are as follows: average revenue is $4.49B (high $4.5B, low $4.48B), average EBITDA is $1.64B (high $1.64B, low $1.63B), average net income is $1.15B (high $1.15B, low $1.14B), average SG&A $1.01B (high $1.01B, low $1.01B), and average EPS is $4.85 (high $4.87, low $4.83).
Did the HOLX's actual financial results beat the analysts' financial forecasts?
Based on Hologic's last annual report (Sep 2023), the company's revenue was $4.03B, beating the average analysts forecast of $3.86B by 4.38%. Apple's EBITDA was $1.2B, missing the average prediction of $1.6B by -25.00%. The company's net income was $456M, missing the average estimation of $978.54M by -53.40%. Apple's SG&A was $987.6M, beating the average forecast of $864.33M by 14.26%. Lastly, the company's EPS was $1.85, missing the average prediction of $3.52 by -47.42%. In terms of the last quarterly report (Dec 2023), Hologic's revenue was $277.9M, missing the average analysts' forecast of $989.32M by -71.91%. The company's EBITDA was $198.2M, missing the average prediction of $360.55M by -45.03%. Hologic's net income was $246.5M, beating the average estimation of $224.62M by 9.74%. The company's SG&A was $260.7M, beating the average forecast of $222.42M by 17.21%. Lastly, the company's EPS was $0.001, missing the average prediction of $0.95 by -99.89%